Related Experiment Video
Updated: Jul 9, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
[Efficacy of adjuvant chemotherapy after left pneumonectomy on non-small cell lung cancer]
Meng Wang1, Chang-Li Wang, Li-Qun Gong
1Department of Thoracic Surgery, Tumor Hospital, Tianjin Medical University, Tianjin, 300060, PR China.
Background & Objective:
Presently, whether non-small cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy after left pneumonectomy is controversial. This study was to evaluate the efficacy of adjuvant chemotherapy after left pneumonectomy on NSCLC, and explore candidate patient selection for adjuvant chemotherapy.
Methods:
Clinical data of 51 NSCLC patients received radical left pneumonectomy and adjuvant chemotherapy of TP/NP regimen and 102 patients received left pneumonectomy alone between Jan. 1997 and Jan. 2002 were compared.
Results:
The 1-, 3-, and 5-year survival rates were 88.2%, 54.9%, and 36.1% in adjuvant chemotherapy group, and 76.5%, 37.3%, and 23.9% in control group (P>0.05). For the patients at stage N2 or IIIA, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients with preoperative forced expiratory volume at the first second (FEV1) of >2 L, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients aged of >65 or < o r =65, there was no significant difference in survival between the two groups (P>0.05).
Conclusions:
For the NSCLC patients at stage IIIA, N2 or with preoperative FEV1 of >2 L, adjuvant chemotherapy after left pneumonectomy may improve survival rate. For the patients with good pulmonary function, even aged patients, adjuvant chemotherapy is needed.
